Shire agrees to more clinical trials for blood pressure drug, but threat of FDA action lingers
One year after Shire (NASDAQ:SHPGY) pulled its drug for low blood pressure, ProAmatine, from the market after reaching an impasse with the U.S. Food and Drug Administration, it has agreed to do the additional clinical tests the regulator wanted. The agreement was made with the Center for Drug Evaluation and Research, a division of the […]